Abstract | AIMS: METHODS: The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) study randomized 15,526 patients with a recent ACS to rivaroxaban 2.5 mg BID, rivaroxaban 5 mg BID, or placebo. An independent clinical events committee adjudicated each MI that occurred during the study and further classified them based on type. Data are presented as two-year Kaplan-Meier event rates and hazard ratios (HRs) and 95% confidence intervals (CI). RESULTS: In total, 665 patients experienced a post-randomization MI. The majority (n=535, 80.5%) were spontaneous (Type 1) events. Rivaroxaban reduced spontaneous MI when compared with placebo (4.4% vs 5.7%, HR 0.80, 95% 0.67-0.95, p=0.01), and there were directionally consistent reductions with both the 2.5 mg BID (4.7% vs 5.7%, HR 0.84, 95% 0.68-1.02, p=0.08) and 5 mg BID doses (4.1% vs 5.7%, HR 0.77, 95% 0.62-0.94, p=0.01) as compared with placebo. Rivaroxaban reduced MI with large elevations in troponin or creatine kinase-MB (CK-MB) fraction (1.8% vs 2.4%, HR 0.73, 95% CI 0.56-0.96, p=0.03) and STEMI events (1.7% vs 2.5%, HR 0.74, 95% CI 0.56-0.99, p=0.04). CONCLUSIONS: In patients stabilized and followed after ACS, the majority of MIs that occur are spontaneous and rivaroxaban significantly reduced the incidence of these events. Notably, rivaroxaban reduced MIs with extensive biomarker release and ST-segment elevation.
|
Authors | Matthew A Cavender, C Michael Gibson, Eugene Braunwald, Stephen D Wiviott, Sabina A Murphy, Eri Toda Kato, Alexei N Plotnikov, Marcos Amuchástegui, Ton Oude Ophuis, Maarten van Hessen, Jessica L Mega |
Journal | European heart journal. Acute cardiovascular care
(Eur Heart J Acute Cardiovasc Care)
Vol. 4
Issue 5
Pg. 468-74
(Oct 2015)
ISSN: 2048-8734 [Electronic] England |
PMID | 25318481
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The European Society of Cardiology 2014. |
Chemical References |
- Biomarkers
- Factor Xa Inhibitors
- Troponin
- Rivaroxaban
- Creatine Kinase, MB Form
|
Topics |
- Acute Coronary Syndrome
(drug therapy, metabolism, pathology)
- Biomarkers
(metabolism)
- Creatine Kinase, MB Form
(metabolism)
- Drug Administration Schedule
- Factor Xa Inhibitors
(administration & dosage)
- Humans
- Middle Aged
- Myocardial Infarction
(diagnosis, drug therapy, metabolism, prevention & control)
- Rivaroxaban
(administration & dosage)
- Secondary Prevention
- Thrombolytic Therapy
(methods)
- Treatment Outcome
- Troponin
(metabolism)
|